MS & Immune Disorders
News
MS Minute: Introducing The New Editors
Barbara S. Giesser, MD, FAAN, FANA; and Lawrence Samkoff, MD, FAAN
January 2019—Our new editors continue their professional collaboration to help advance care of patients with MS.
Cognitive Complaints and Neuropsychologic Testing
Nabil Ali, MD; Kendra Corning, PsyD, HSPP; and Laura M. Clark, PhD, ABPP
January 2019—When should neuropsychologic tests be ordered and what questions should testing answer?
Neurosyphilis-Induced Psychosis
Veronica Hocker, MD; and Nabil Ali, MD
January 2019—The return of the great imitator makes it critical to know the guidelines for testing for neurosyphilis.
Case Report: Longitudinally Extensive Transverse Myelitis
Lakshmi Leishangthem, MD; Pooja SirDeshpande, MD; Saman Zafar, MD; Ylec Mariana Cardenas, MD; Aparna Prabhu, MD; and David Roby, MD
January 2019—The borderline of neuromyelitis optica and systemic lupus erythematosus.
Gray Matter Atrophy in Multiple Sclerosis May Occur Independently of Clinically Effective Treatment
Friday, December 21, 2018—Once thought to be a disease only of white matter, the myelin sheath of oligoglia, it is now accepted that multiple sclerosis (MS) affects nerve cells themselves, the gray mat…
New Drug Application Submitted for Therapy for Multiple Sclerosis
Tuesday, December 18, 2018—A New Drug Application (NDA) has been submitted to the US Food and Drug Administration (FDA) for diroximel fumarate (BIIB098/Vumerity; Alkermes PLC, Waltham, MA), a novel oral…
FDA Approves Amifampridine for Lambert-Eaton Myasthenic Syndrome
Monday, December 03, 2018—The FDA has approved amifampridine (Firdapse, Catalyst Pharmaceuticals, Coral Gables, FL) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. This…
Warning Issued for Possible Stroke Risk When Starting Alemtuzumab
Friday, November 30, 2018—The Food and Drug Administration (FDA) has issued a warning about possible risk of stroke and neurovascular injury for patients starting treatment with alemtuzumab (Lemtrada, …
